Japan relies almost entirely on China for the APIs of β-lactam antibiotics. These drugs are essential for treating infectious diseases…
REGULATORY
As Kymriah Fetches Highest List Price, Policymakers Talk over Difficulty in Cell Therapy Pricing
As Novartis Pharma’s CAR-T cell therapy Kymriah (tisagenlecleucel) received the highest NHI price of nearly 33.5 million yen, policymakers discussed difficulties surrounding the pricing of cell and gene therapies under the current rules at a meeting of a key reimbursement…
To read the full story
Related Article
REGULATORY
- Japan Picks 14 “Loss” Products as Drugs with Highest Priority for Development
April 2, 2025
- GSK’s Shingrix Buttresses Label with Long-Term Data
April 2, 2025
- MHLW Says It Will Handle Info Disclosure Requests as per Rules
April 2, 2025
- MHLW Doles Out Orphan Tags to 12 Compounds
April 1, 2025
- J&J’s Opsumit Designated as Drug for Specific Use: MHLW
April 1, 2025
Your company’s employer brand is your reputation as an employer and is crucial in attracting top talent. Some reputations are just not good; they may or not be deserved. That is just the perception in the market. Years ago there…
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…